Horminone

Horminone

SCHEMBL22861860

CC(C)C1=C(O)C(=O)C2=C(C1=O)[C@@H](O)C[C@H]1C(C)(C)CCC[C@]21C

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 3/20 0.45
▸ EP300 Q09472 1/20 0.39
▸ FDPS P14324 8/20 0.35
▸ MEN1 O00255 2/20 0.33
▸ USP2 O75604 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ GGPS1 O95749 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ PTGES O14684 1/20 0.33
▸ PNLIP P16233 1/20 0.33
▸ CDC25A P30304 1/20 0.32
▸ DUSP3 P51452 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Horminone SCHEMBL22861891 1.00 CYP19A1 (0.45) CYP19A1EP300FDPSMEN1USP2
SCHEMBL30088312 0.90 CYP19A1 (0.45) CYP19A1EP300FDPSMEN1USP2
SCHEMBL22472964 0.85 CYP19A1 (0.35) CYP19A1EP300FDPSMEN1KMT2A
SCHEMBL22861892 0.82 FDPS (0.39) CYP19A1EP300FDPSGGPS1TP53
SCHEMBL14303936 0.79 EP300 (0.40) CYP19A1EP300FDPSGGPS1
SCHEMBL21291505 0.78 EP300 (0.40) CYP19A1EP300FDPSMEN1USP2
Royleanone SCHEMBL16006778 0.77 CYP3A4 (0.44) CYP19A1EP300FDPSMEN1USP2
Royleanone SCHEMBL21291506 0.77 CYP3A4 (0.44) CYP19A1EP300FDPSMEN1USP2
SCHEMBL22861886 0.75 EP300 (0.38) CYP19A1EP300FDPSGGPS1
SCHEMBL22861890 0.75 EP300 (0.38) CYP19A1EP300FDPSGGPS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210000841-A1 COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2021-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210000841-A1 COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS F5, F2, F3 CYP19A1 1873/4885EP300 4632/4885FDPS 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback